AAPL339.75+0.77 (+0.23%) ▲|ABBV265.21+0.73 (+0.28%) ▲|ABT103.69+0.71 (+0.69%) ▲|ACN183.72-2.39 (-1.28%) ▼|ADBE238.25-11.27 (-4.52%) ▼|AMAT472.46+8.22 (+1.77%) ▲|AMD623.77+8.25 (+1.34%) ▲|AMGN410.24+17.08 (+4.34%) ▲|AMT175.25+0.65 (+0.37%) ▲|AMZN254.98-3.47 (-1.34%) ▼|AVGO364.54+1.88 (+0.52%) ▲|AXP305.07-8.52 (-2.72%) ▼|BA197.72-3.43 (-1.71%) ▼|BAC56.20-1.76 (-3.04%) ▼|BKNG164.22-4.30 (-2.55%) ▼|BLK1,066.66-23.61 (-2.17%) ▼|BMY62.25-0.37 (-0.59%) ▼|BNY150.17-3.72 (-2.42%) ▼|BRK-B503.49+1.48 (+0.29%) ▲|C132.47-2.58 (-1.91%) ▼|CAT808.01-8.49 (-1.04%) ▼|CL87.05+0.79 (+0.92%) ▲|CMCSA22.42-0.51 (-2.22%) ▼|COF200.55-4.37 (-2.13%) ▼|COP125.27-2.26 (-1.77%) ▼|COST899.41+0.93 (+0.10%) ▲|CRM233.28-3.14 (-1.33%) ▼|CSCO106.44-5.02 (-4.50%) ▼|CVS87.10-0.50 (-0.57%) ▼|CVX202.41-1.26 (-0.62%) ▼|DE703.12+18.39 (+2.69%) ▲|DHR221.09+5.25 (+2.43%) ▲|DIS103.82-0.41 (-0.39%) ▼|DUK116.31-0.43 (-0.37%) ▼|EMR154.19+2.47 (+1.63%) ▲|FDX295.94+0.15 (+0.05%) ▲|GD343.39-10.51 (-2.97%) ▼|GE319.22+0.21 (+0.07%) ▲|GEV950.28+4.06 (+0.43%) ▲|GILD152.67+2.11 (+1.40%) ▲|GM83.45-0.50 (-0.60%) ▼|GOOG347.41-3.46 (-0.99%) ▼|GOOGL351.16-3.81 (-1.07%) ▼|GS949.49-9.90 (-1.03%) ▼|HD305.35+8.15 (+2.74%) ▲|HON211.85+5.37 (+2.60%) ▲|IBM231.38-0.55 (-0.24%) ▼|INTC123.86+2.08 (+1.71%) ▲|INTU292.35-11.77 (-3.87%) ▼|ISRG402.09+0.44 (+0.11%) ▲|JNJ269.19-0.28 (-0.10%) ▼|JPM340.00-12.04 (-3.42%) ▼|KO88.61+1.49 (+1.71%) ▲|LIN464.91+7.41 (+1.62%) ▲|LLY1,170.14+5.25 (+0.45%) ▲|LMT522.34-13.06 (-2.44%) ▼|LOW196.08+5.10 (+2.67%) ▲|LRCX310.96+8.68 (+2.87%) ▲|MA555.89-11.76 (-2.07%) ▼|MCD250.35+2.47 (+1.00%) ▲|MDLZ61.08+0.91 (+1.51%) ▲|MDT90.77-0.98 (-1.07%) ▼|META736.60-4.65 (-0.63%) ▼|MMM169.30+4.33 (+2.62%) ▲|MO68.64+0.11 (+0.16%) ▲|MRK150.91+1.41 (+0.94%) ▲|MS200.18-5.94 (-2.88%) ▼|MSFT498.00-3.61 (-0.72%) ▼|MU1,096.16+52.20 (+5.00%) ▲|NEE79.26-0.37 (-0.46%) ▼|NFLX72.16-1.20 (-1.64%) ▼|NKE36.10+0.00 (+0.00%) ▲|NOW137.00-0.68 (-0.49%) ▼|NVDA228.87+1.49 (+0.66%) ▲|ORCL149.20+0.64 (+0.43%) ▲|PEP131.19+1.60 (+1.23%) ▲|PFE27.93+0.19 (+0.68%) ▲|PG148.22+2.14 (+1.47%) ▲|PLTR184.99+1.92 (+1.05%) ▲|PM190.23+2.75 (+1.47%) ▲|QCOM198.27+4.04 (+2.08%) ▲|RTX190.99-3.35 (-1.72%) ▼|SBUX95.11+0.21 (+0.22%) ▲|SCHW100.35-6.53 (-6.11%) ▼|SO85.15-0.31 (-0.36%) ▼|SPG205.95+0.97 (+0.47%) ▲|T25.10-0.35 (-1.38%) ▼|TMO658.52-0.24 (-0.04%) ▼|TMUS162.41-2.86 (-1.73%) ▼|TSLA378.90+3.69 (+0.98%) ▲|TXN271.41+0.54 (+0.20%) ▲|UBER69.89-0.95 (-1.34%) ▼|UNH372.95-4.61 (-1.22%) ▼|UNP274.41+4.78 (+1.77%) ▲|UPS95.87+1.12 (+1.18%) ▲|USB59.44-1.00 (-1.65%) ▼|V362.04-7.91 (-2.14%) ▼|VZ46.45-1.23 (-2.58%) ▼|WFC83.15-3.39 (-3.92%) ▼|WMT110.12+2.68 (+2.49%) ▲|XOM158.71+0.41 (+0.26%) ▲|AAPL339.75+0.77 (+0.23%) ▲|ABBV265.21+0.73 (+0.28%) ▲|ABT103.69+0.71 (+0.69%) ▲|ACN183.72-2.39 (-1.28%) ▼|ADBE238.25-11.27 (-4.52%) ▼|AMAT472.46+8.22 (+1.77%) ▲|AMD623.77+8.25 (+1.34%) ▲|AMGN410.24+17.08 (+4.34%) ▲|AMT175.25+0.65 (+0.37%) ▲|AMZN254.98-3.47 (-1.34%) ▼|AVGO364.54+1.88 (+0.52%) ▲|AXP305.07-8.52 (-2.72%) ▼|BA197.72-3.43 (-1.71%) ▼|BAC56.20-1.76 (-3.04%) ▼|BKNG164.22-4.30 (-2.55%) ▼|BLK1,066.66-23.61 (-2.17%) ▼|BMY62.25-0.37 (-0.59%) ▼|BNY150.17-3.72 (-2.42%) ▼|BRK-B503.49+1.48 (+0.29%) ▲|C132.47-2.58 (-1.91%) ▼|CAT808.01-8.49 (-1.04%) ▼|CL87.05+0.79 (+0.92%) ▲|CMCSA22.42-0.51 (-2.22%) ▼|COF200.55-4.37 (-2.13%) ▼|COP125.27-2.26 (-1.77%) ▼|COST899.41+0.93 (+0.10%) ▲|CRM233.28-3.14 (-1.33%) ▼|CSCO106.44-5.02 (-4.50%) ▼|CVS87.10-0.50 (-0.57%) ▼|CVX202.41-1.26 (-0.62%) ▼|DE703.12+18.39 (+2.69%) ▲|DHR221.09+5.25 (+2.43%) ▲|DIS103.82-0.41 (-0.39%) ▼|DUK116.31-0.43 (-0.37%) ▼|EMR154.19+2.47 (+1.63%) ▲|FDX295.94+0.15 (+0.05%) ▲|GD343.39-10.51 (-2.97%) ▼|GE319.22+0.21 (+0.07%) ▲|GEV950.28+4.06 (+0.43%) ▲|GILD152.67+2.11 (+1.40%) ▲|GM83.45-0.50 (-0.60%) ▼|GOOG347.41-3.46 (-0.99%) ▼|GOOGL351.16-3.81 (-1.07%) ▼|GS949.49-9.90 (-1.03%) ▼|HD305.35+8.15 (+2.74%) ▲|HON211.85+5.37 (+2.60%) ▲|IBM231.38-0.55 (-0.24%) ▼|INTC123.86+2.08 (+1.71%) ▲|INTU292.35-11.77 (-3.87%) ▼|ISRG402.09+0.44 (+0.11%) ▲|JNJ269.19-0.28 (-0.10%) ▼|JPM340.00-12.04 (-3.42%) ▼|KO88.61+1.49 (+1.71%) ▲|LIN464.91+7.41 (+1.62%) ▲|LLY1,170.14+5.25 (+0.45%) ▲|LMT522.34-13.06 (-2.44%) ▼|LOW196.08+5.10 (+2.67%) ▲|LRCX310.96+8.68 (+2.87%) ▲|MA555.89-11.76 (-2.07%) ▼|MCD250.35+2.47 (+1.00%) ▲|MDLZ61.08+0.91 (+1.51%) ▲|MDT90.77-0.98 (-1.07%) ▼|META736.60-4.65 (-0.63%) ▼|MMM169.30+4.33 (+2.62%) ▲|MO68.64+0.11 (+0.16%) ▲|MRK150.91+1.41 (+0.94%) ▲|MS200.18-5.94 (-2.88%) ▼|MSFT498.00-3.61 (-0.72%) ▼|MU1,096.16+52.20 (+5.00%) ▲|NEE79.26-0.37 (-0.46%) ▼|NFLX72.16-1.20 (-1.64%) ▼|NKE36.10+0.00 (+0.00%) ▲|NOW137.00-0.68 (-0.49%) ▼|NVDA228.87+1.49 (+0.66%) ▲|ORCL149.20+0.64 (+0.43%) ▲|PEP131.19+1.60 (+1.23%) ▲|PFE27.93+0.19 (+0.68%) ▲|PG148.22+2.14 (+1.47%) ▲|PLTR184.99+1.92 (+1.05%) ▲|PM190.23+2.75 (+1.47%) ▲|QCOM198.27+4.04 (+2.08%) ▲|RTX190.99-3.35 (-1.72%) ▼|SBUX95.11+0.21 (+0.22%) ▲|SCHW100.35-6.53 (-6.11%) ▼|SO85.15-0.31 (-0.36%) ▼|SPG205.95+0.97 (+0.47%) ▲|T25.10-0.35 (-1.38%) ▼|TMO658.52-0.24 (-0.04%) ▼|TMUS162.41-2.86 (-1.73%) ▼|TSLA378.90+3.69 (+0.98%) ▲|TXN271.41+0.54 (+0.20%) ▲|UBER69.89-0.95 (-1.34%) ▼|UNH372.95-4.61 (-1.22%) ▼|UNP274.41+4.78 (+1.77%) ▲|UPS95.87+1.12 (+1.18%) ▲|USB59.44-1.00 (-1.65%) ▼|V362.04-7.91 (-2.14%) ▼|VZ46.45-1.23 (-2.58%) ▼|WFC83.15-3.39 (-3.92%) ▼|WMT110.12+2.68 (+2.49%) ▲|XOM158.71+0.41 (+0.26%) ▲|
18.9 C
New York
Tuesday, September 22, 2026

Tag: program

newssourceFORcompanyinformationcontent1releasesmarket

Emollient Market worth $4.08 billion by 2030 – Exclusive Report by MarketsandMarkets™

DELRAY BEACH, Fla., June 23, 2025 /PRNewswire/ -- The report "Emollient Market by Type (Esters, Fatty Alcohols, Fatty Acids, Ethers, Silicones, and Other Types), Form...

U.S. Dermatology Partners Opens New Location in Osage Beach, Missouri

U.S. Dermatology Partners expands access to dermatology care in the Lake of the Ozarks region with the opening of its newest office. OSAGE BEACH, Mo.,...

Kanazawa University research: From hydration layers to nanoarchitectures: Water’s pivotal role in peptide organization on 2D nanomaterials

KANAZAWA, Japan, June 23, 2025 /PRNewswire/ -- Researchers at the Nano Life Science Institute (WPI-NanoLSI), Kanazawa University, report in Small, a weekly peer-reviewed scientific...

Intellipaat launches India’s First DevSecOps Program with Generative & Agentic AI

BANGALORE, India, June 23, 2025 /PRNewswire/ -- Intellipaat, a global leader in professional upskilling, has launched a groundbreaking transformation of its flagship DevOps program,...

Aetna Supports Industry Actions to Simplify Prior Authorization

Company commits to distinctive actions that will make it easier to navigate the health care system, access care, and achieve better healthHARTFORD, Conn., June...

ITM and Debiopharm Announce First Patient Imaged in New Study Arm of Phase 1/2 Trial Evaluating ITM-94 as Diagnostic Agent for Clear Cell Renal...


Garching / Munich, Germany, and Lausanne, Switzerland - June 23, 2025 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company and Debiopharm, a Swiss-based, global biopharmaceutical company aiming to establish tomorrow’s standard-of-care to cure cancer and infectious diseases, today announced that the first patient was imaged in a new study arm of a five-part, Phase 1/2 clinical trial (formerly GaLuCi™) (NCT05706129) evaluating the theranostic pair ITM-94/ITM-91 for identification and treatment of patients who have unresectable, locally advanced or metastatic solid tumors. As a new component of a broad clinical development plan for ITM-91/ITM-94, Part D of the trial will evaluate the effectiveness of ITM-94 in classifying indeterminate renal mass as either ccRCC or non-cancerous.

Share repurchase programme: Transactions of week 25 2025

The share repurchase programme runs as from 26 February 2025 and up to and including 30 January 2026 at the latest. In this period, Jyske Bank will acquire shares with a value of up to DKK 2.25 billion, cf. Corporate Announcement No. 3/2025 of 26 February 2025. The share repurchase programme is initiated and structured in compliance with the EU Commission Regulation No. 596/2014 of 16 April 2014, the so-called “Market Abuse Regulation”, and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (together with the Market Abuse Regulation, the "Safe Harbour Rules").

Indonesian DPR Immerses in Shenzhen’s Cutting-Edge Tech during SZMG’s “Telling China’s Story” Event, Calls for Deeper China-Indonesia Cooperation.

SHENZHEN, China, June 23, 2025 /PRNewswire/ -- This year marks the 75th anniversary of the establishment of diplomatic relations between China and Indonesia. Telling...

Fletcher Zone Maiden Mineral Resource of 2.3Moz

Stage 1 Fletcher Resource almost doubles the current Beta Hunt Resource PERTH, Western Australia, June 23, 2025 /CNW/ - Westgold Resources Limited (ASX: WGX) (TSX: WGX)...

Shareholders who own 3D Systems (NYSE: DDD) Should Contact Wolf Haldenstein

NEW YORK, June 22, 2025 (GLOBE NEWSWIRE) -- Wolf Haldenstein Adler Freeman & Herz LLP announces that securities class action lawsuit has been filed in the United States District Court for the District of Delaware on behalf of all persons or entities who purchased or otherwise acquired 3D Systems Corporation (3D Systems or the Company) (NYSE: DDD) securities between August 13, 2024 and May 12, 2025, inclusive (the Class Period).

Oral Semaglutide Significantly Improves Cardiovascular Outcomes in Individuals with Type 2 Diabetes

Oral formulation demonstrates comparable cardiovascular benefits to injectable GLP-1s CHICAGO, June 22, 2025 /PRNewswire/ -- A recent study found that oral semaglutide offers meaningful cardiovascular benefits...

Mim8 prophylaxis treatment shown to be well-tolerated when switching from emicizumab in people with hemophilia A in new phase 3 data presented at the...

New FRONTIER5 results show a direct switch to investigational Mim8 (denecimig) prophylaxis treatment from emicizumab, without the need for a washout period, was well-tolerated...

Lilly’s once-weekly insulin efsitora alfa demonstrated A1C reduction and a safety profile consistent with daily insulin in multiple Phase 3 trials

Results from the fixed-dose QWINT-1 study, along with the QWINT-3 and QWINT-4 studies, reinforce efsitora's potential to simplify insulin management with weekly dosing Lilly plans...

Once-Weekly Insulin Efsitora Achieves Comparable A1C Reduction to Daily Insulin Therapy

Once-weekly insulin helped patients achieve an average A1C of 6.92% in QWINT-1 trial Results support once-weekly insulin as effective alternative to daily treatment CHICAGO, June 22,...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsProgram

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers